Related references
Note: Only part of the references are listed.Metabolic syndrome in people with schizophrenia: a review
MARC DE HERT et al.
World Psychiatry (2015)
Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice
John W. Newcomer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Depression and Risk of Mortality in People with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Fleur E. P. van Dooren et al.
PLOS ONE (2013)
Weight Considerations in Psychotropic Drug Prescribing and Switching
Mehrul Hasnain et al.
POSTGRADUATE MEDICINE (2013)
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders-A Systematic Review and Meta-Analysis
Alex J. Mitchell et al.
SCHIZOPHRENIA BULLETIN (2013)
A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications
Michael Beary et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
T. Scott Stroup et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
Angela L. Hill et al.
BMC PSYCHIATRY (2011)
Dose Pattern and Effectiveness of Paliperidone Extended-Release Tablets in Patients With Schizophrenia
Jung-Sun Lee et al.
CLINICAL NEUROPHARMACOLOGY (2011)
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder
T. A. Hardy et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study
Brian Bortnick et al.
JOURNAL OF AFFECTIVE DISORDERS (2011)
A Double-Blind, Randomized Study Comparing the Efficacy and Safety of Sertindole and Risperidone in Patients With Treatment-Resistant Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
A Dose Comparison of Olanzapine for the Treatment of Borderline Personality Disorder: A 12-Week Randomized, Double-Blind, Placebo-Controlled Study
Mary C. Zanarini et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo
Marianne Klemp et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
Jean-Pierre Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Open-Label Trial of Aripiprazole in the Treatment of Trichotillomania
Matthew P. White et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Switching from Quetiapine to Ziprasidone: A Sixteen-Week, Open-Label, Multicenter Study Evaluating the Effectiveness and Safety of Ziprasidone in Outpatient Subjects with Schizophrenia or Schizoaffective Disorder
Onur N. Karayal et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2011)
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
S. Gopal et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Weight Changes and their Associations with Demographic and Clinical Characteristics in Risperidone Maintenance Treatment for Schizophrenia
Y. -T. Xiang et al.
PHARMACOPSYCHIATRY (2011)
A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test
Chun-Hsin Chen et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
Gahan Pandina et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes
Serge Sevy et al.
PSYCHIATRY RESEARCH (2011)
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder
William Victor Bobo et al.
PSYCHIATRY RESEARCH (2011)
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
Xiaofeng Guo et al.
PSYCHOPHARMACOLOGY (2011)
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder
Steven G. Potkin et al.
SCHIZOPHRENIA RESEARCH (2011)
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Mario Rodrigues Louza et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2011)
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
John M. Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial
Subhrojyoti Bhowmick et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2010)
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Jorge A. Quiroz et al.
BIOLOGICAL PSYCHIATRY (2010)
Effect of overweight on gastrointestinal microbiology and immunology: correlation with blood biomarkers
Kirsti Tiihonen et al.
BRITISH JOURNAL OF NUTRITION (2010)
Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia
Sung-Wan Kim et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial
Jaewon Yang et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Body mass index, waist circumference and waist: hip ratio as predictors of cardiovascular risk-a review of the literature
R. Huxley et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2010)
Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea
J. C. Seidell
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2010)
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial
William V. Bobo et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2010)
Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
Eduard Parellada et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2010)
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone
Carla M. Canuso et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2010)
Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2010)
Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2010)
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression
Trisha Suppes et al.
JOURNAL OF AFFECTIVE DISORDERS (2010)
Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial
David E. Kemp et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania
Michael Van Ameringen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
C. Bushe et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
J. Schoemaker et al.
PHARMACOPSYCHIATRY (2010)
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine
Chih-Chiang Chiu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia
Herbert Y. Meltzer et al.
PSYCHIATRY RESEARCH (2010)
Weight gain in antipsychotic-naive patients: a review and meta-analysis
I. Tarricone et al.
PSYCHOLOGICAL MEDICINE (2010)
The cumulative needs for care monitor: a unique monitoring system in the south of the Netherlands
Marjan Drukker et al.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2010)
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
Istvan Bitter et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2010)
A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
Ming-Hong Hsieh et al.
ANNALS OF GENERAL PSYCHIATRY (2010)
Obesity Among Those with Mental Disorders A National Institute of Mental Health Meeting Report
David B. Allison et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2009)
A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia
W. Wolfgang Fleischhacker et al.
BIOLOGICAL PSYCHIATRY (2009)
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
Roger S. McIntyre et al.
BIPOLAR DISORDERS (2009)
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Allan H. Young et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study
Donald E. Addington et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2009)
Efficacy and Tolerability of Aripiprazole in First-Episode Drug-Naive Patients With Schizophrenia: An Open-Label Trial
Hitoshi Takahashi et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Richard Weisler et al.
CNS SPECTRUMS (2009)
Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia
Jamie Karagianis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Obesity, serious mental illness and antipsychotic drugs
Richard I. G. Holt et al.
DIABETES OBESITY & METABOLISM (2009)
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study
Chi-Un Pae et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Belgian Schizophrenia Outcome Survey - Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol
J. Peuskens et al.
EUROPEAN PSYCHIATRY (2009)
How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins
F. C. J. Starrenburg et al.
EUROPEAN PSYCHIATRY (2009)
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
Sung-Wan Kim et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
Kyoung-Uk Lee et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
Alessandro Rossi et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia
Hans-Jürgen Möller et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study
Koksal Alptekin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
David V. Sheehan et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study
P. E. Keck et al.
JOURNAL OF AFFECTIVE DISORDERS (2009)
The Moderating Impact of Ethnicity on Metabolic Outcomes During Treatment With Olanzapine and Aripiprazole in Patients With Schizophrenia
Jonathan M. Meyer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study
Robert C. Smith et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Obesity in Patients With Severe Mental Illness: Overview and Management
Susan L. McElroy
JOURNAL OF CLINICAL PSYCHIATRY (2009)
A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone
John W. Newcomer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses
John W. Newcomer
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Mitsutaka Nakamura et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Jari Tiihonen et al.
LANCET (2009)
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
Dennis H. Kim et al.
NEUROTHERAPEUTICS (2009)
Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications
S. Gentile
OBESITY REVIEWS (2009)
Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
V. Ryckmans et al.
PHARMACOPSYCHIATRY (2009)
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
S. Leucht et al.
PSYCHOLOGICAL MEDICINE (2009)
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever
Michael Kluge et al.
PSYCHONEUROENDOCRINOLOGY (2009)
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol
Menahem Krakowski et al.
SCHIZOPHRENIA RESEARCH (2009)
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study
J. Karagianis et al.
SCHIZOPHRENIA RESEARCH (2009)
Influence of antipsychotics on mortality in schizophrenia: Systematic review
Stefan Weinmann et al.
SCHIZOPHRENIA RESEARCH (2009)
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
Emilio Sacchetti et al.
SCHIZOPHRENIA RESEARCH (2009)
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
Kotaro Hatta et al.
SCHIZOPHRENIA RESEARCH (2009)
Results of phase 3 of the CATIE schizophrenia trial
T. Scott Stroup et al.
SCHIZOPHRENIA RESEARCH (2009)
Weight effects associated with antipsychotics: A comprehensive database analysis
Bruce Parsons et al.
SCHIZOPHRENIA RESEARCH (2009)
Olanzapine orally disintegrating tablets (Zyprexa Zydis(R)) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study
Hikaru Hori et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2009)
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study
Tamas Treuer et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2009)
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia
S. Saddichha et al.
ACTA PSYCHIATRICA SCANDINAVICA (2008)
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
Joel E. Streim et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine
Deanna L. Kelly et al.
ANNALS OF CLINICAL PSYCHIATRY (2008)
Quetiapine for the treatment of bipolar mania in older adults
Martha Sajatovic et al.
BIPOLAR DISORDERS (2008)
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
Ruud van Winkel et al.
BIPOLAR DISORDERS (2008)
Effectiveness of second generation antipsychotics: A systematic review of randomized trials
Erik Johnsen et al.
BMC PSYCHIATRY (2008)
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
S. Charles Schulz et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Non-pharmacological management of anti psychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials
Mario Alvarez-Jimenez et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders - A systematic critical reappraisal
Mario Alvarez-Jimenez et al.
CNS DRUGS (2008)
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
Douglas E. Faries et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial
Bharat Chawla et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2008)
Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients
Rao N. Malempati et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone
Carla M. Canuso et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
Robin Emsley et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Weight gain during olanzapine treatment for psychotic depression: effects of dose and age
Eric Smith et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study
D. J. Muzina et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men
Tsafrir Loebl et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
John W. Newcomer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
John Lauriello et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies
Herbert Y. Meltzer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: Aripiprazole versus standard of care
Lawrence Blonde et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Aripiprazole therapy in 20 older adults with bipolar disorder: A 12-week, open-label trial
Martha Sajatovic et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial
Susan L. McElroy et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Comorbid somatic illnesses in patients with severe mental disorders:: Clinical, policy, and research challenges
W. Wolfgang Fleischhacker et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia
Herbert Y. Meltzer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Prolactin-related and metabolic adverse effects of atypical antipsychotic agents
David C. Henderson et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Aripiprazole monotherapy in non-psychotic bipolar I depression
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels
James L. Roerig et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis - A preliminary study
Robin Emsley et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder - A randomized, double-blind, fixed-dose study
Bruce J. Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill Patients With Schizophrenia
Bruce J. Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Long-term efficacy and safety of iloperidone - Results from 3 clinical trials for the treatment of schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Safety profile of iloperidone - A pooled analysis of 6-week acute-phase pivotal trials
Peter J. Weiden et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia
Marilyn Ader et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study
Josep Maria Haro et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
A Double-blind Placebo-controlled Discontinuation Study of Zuclopenthixol for the Treatment of Aggressive Disruptive Behaviours in Adults with Mental Retardation - Secondary Parameter Analyses
F. Haessler et al.
PHARMACOPSYCHIATRY (2008)
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2008)
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial
Emilio Sacchetti et al.
SCHIZOPHRENIA RESEARCH (2008)
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
Karen A. Graham et al.
SCHIZOPHRENIA RESEARCH (2008)
Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study
Stephen R. Marder et al.
BIOLOGICAL PSYCHIATRY (2007)
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
Joseph P. McEvoy et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2007)
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study
Dan Zimbroff et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2007)
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone
Rocio Perez-Iglesias et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
A systematic review of mortality in schizophrenia - Is the differential mortality gap worsening over time?
Sukanta Saha et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia
Michael Riedel et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2007)
Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial
Steven G. Potkin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial
Sung-Wan Kim et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
Robert Kerwin et al.
EUROPEAN PSYCHIATRY (2007)
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo
Paul E. Keck et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Ziprasidone in treatment-resistant schizophrenia: A 52-week, open-label continuation study
Antony D. Loebel et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
Changsu Han et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
Nicholas A. Keks et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
Olanzapine versus chlorpromazine in the treatment of schizophrenia - A pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
Martin Dossenbach et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis
Martin Strassnig et al.
SCHIZOPHRENIA RESEARCH (2007)
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia
Trino Baptista et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2007)
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
Michael Davidson et al.
SCHIZOPHRENIA RESEARCH (2007)
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms
Stephan Ruhrmann et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
Joseph Peuskens et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2007)
Ziprasidone outcome and tolerability: A practical clinical trial with plasma drug levels
M. C. Mauri et al.
PHARMACOPSYCHIATRY (2007)
Outcomes for Latin American versus white patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol
Jorge M. Tamayo et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Weight development in patients treated with risperidone:: a 5-year naturalistic study
M. Neovius et al.
ACTA PSYCHIATRICA SCANDINAVICA (2007)
A Randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia
Jean-Pierre Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia - A randomized, double-blind, placebo-controlled study
Michelle Kramer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial
J. Kane et al.
SCHIZOPHRENIA RESEARCH (2007)
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
Jean-Pierre Lindenmayer et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A Randomized trial
Hung-Yu Chan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia
Trino Baptista et al.
SCHIZOPHRENIA RESEARCH (2007)
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients
B. Arranz et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2007)
Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study
E. Vieta et al.
BIPOLAR DISORDERS (2007)
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Josep Maria Haro et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Risperidone monotherapy in manic inpatients: An open label, multicentre trial
Anna Forsthoff et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2007)
Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia
Vera Popovic et al.
NEUROENDOCRINOLOGY (2007)
Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in 1 year randomized, open-label trial
Antonio Ciudad et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression
J. -M. Vanelle et al.
EUROPEAN PSYCHIATRY (2006)
Efficacy of quetiapine monotherapy in bipolar I and II depression - A double-blind, placebo-controlled study (The BOLDER II study)
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
Wlodzimierz K. Chrzanowski et al.
PSYCHOPHARMACOLOGY (2006)
Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: A randomized, double-blind trial
Roy H. Perlis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial
Y. Lecrubier et al.
ACTA PSYCHIATRICA SCANDINAVICA (2006)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
Lon S. Schneider et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study
Xiaohong Wang et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2006)
The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients
Chih-Chiang Chiu et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
Beat Nick et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2006)
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study
Kate X. Zhong et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study
Gary Sachs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
Steven G. Potkin et al.
SCHIZOPHRENIA RESEARCH (2006)
The metabolic effects of antipsychotic medications
John W. Newcomer et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2006)
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study
Rael D. Strous et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2006)
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia
Enrique Alvarez et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Early predictors of substantial weight gain in bipolar patients treated with olanzapine
Ilya Lipkovich et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia
C Lee et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2006)
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
BJ Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Obesity among individuals with serious mental illness
FB Dickerson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2006)
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine
M Tohen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study
AF Christensen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2006)
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
RSE Keefe et al.
BIOLOGICAL PSYCHIATRY (2006)
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
JM Kane et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
H Hosojima et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia
JM Azorin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
RB Zipursky et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
Clozapine-induced weight gain:: a study in monozygotic twins and same-sex sib pairs
FM Theisen et al.
PSYCHIATRIC GENETICS (2005)
Amoxapine as an atypical antipsychotic: A comparative study vs risperidone
R Apiquian et al.
NEUROPSYCHOPHARMACOLOGY (2005)
A 6-month prospective observational study on the effects of quetiapine on sexual functioning
ALM González et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: Impulsivity as main target
E Villeneuve et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Aripiprazole for the treatment of psychosis in patients with Alzheimer's Disease - A randomized, placebo-controlled study
P De Deyn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine
M Gastpar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2005)
Long-acting risperidone in stable patients with schizoaffective disorder
A Mohl et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2005)
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia
GM Simpson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
I Gasquet et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Quality of life in schizophrenia: A multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics
MS de Lima et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
RR Conley et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Metabolic issues in patients with severe mental illness
L Citrome et al.
SOUTHERN MEDICAL JOURNAL (2005)
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
JR Calabrese et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder
J Soler et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
The association of weight gain and olanzapine plasma concentrations
PJ Perry et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders
BJ Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial
N Schooler et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study
M Lambert et al.
ACTA PSYCHIATRICA SCANDINAVICA (2005)
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia
D Naber et al.
ACTA PSYCHIATRICA SCANDINAVICA (2005)
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open- label study
Miguel Herrera-Estrella et al.
BMC PSYCHIATRY (2005)
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
Haya Ascher-Svanum et al.
BMC PSYCHIATRY (2005)
Olanzapine increases plasma ghrelin level in patients with schizophrenia
M Murashita et al.
PSYCHONEUROENDOCRINOLOGY (2005)
Potential effectiveness and safety of olanzapine in refractory panic disorder
M Hollifield et al.
DEPRESSION AND ANXIETY (2005)
Olanzapine treatment of residual positive and negative symptoms
RW Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Clinical outcome and olanzapine plasma levels in acute schizophrenia
MC Mauri et al.
EUROPEAN PSYCHIATRY (2005)
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
AB Smulevich et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
P Chue et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants
HY Lane et al.
PSYCHOPHARMACOLOGY (2004)
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
PF Buckley et al.
SCHIZOPHRENIA RESEARCH (2004)
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
PP De Deyn et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2004)
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
BJ Kinon et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2004)
Weight decline in patients switching from olanzapine to quetiapine
S Gupta et al.
SCHIZOPHRENIA RESEARCH (2004)
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
L de Haan et al.
PSYCHOPHARMACOLOGY (2004)
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial
E Sacchetti et al.
SCHIZOPHRENIA RESEARCH (2004)
A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women
DB Reich et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Metabolic risk during antipsychotic treatment
JW Newcomer
CLINICAL THERAPEUTICS (2004)
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder
R Lasser et al.
JOURNAL OF AFFECTIVE DISORDERS (2004)
Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine
B Appelberg et al.
EUROPEAN PSYCHIATRY (2004)
Weight gain during treatment of bipolar I patients with olanzapine
J Hennen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial
DEN Addington et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Switching elderly chronic psychotic patients to olanzapine
Y Barak et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
RA Lasser et al.
EUROPEAN PSYCHIATRY (2004)
Acute and continuation risperidone monotherapy in mania
E Vieta et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2004)
Weight gain with clozapine compared to first generation antipsychotic medications
NH Covell et al.
SCHIZOPHRENIA BULLETIN (2004)
Serious cardiovascular events and mortality among patients with schizophrenia
C Enger et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2004)
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
I Bitter et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2004)
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
CM Beasley et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
S Kasper et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2003)
Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial
NY Chiu et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2003)
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
TA Pigott et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
PE Keck et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Antipsychotic-induced weight gain: Bipolar disorder and leptin
RS McIntyre et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Olanzapine versus placebo in acute mania - Treatment responses in subgroups
RJ Baldessarini et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol:: results of the EIRE study
J Bobes et al.
SCHIZOPHRENIA RESEARCH (2003)
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
SG Potkin et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
SR Marder et al.
SCHIZOPHRENIA RESEARCH (2003)
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
BJ Kinon et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2003)
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
PJ Weiden et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia
CW Ritchie et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
The efficacy and safety of olanzapine for the treatment of geriatric psychosis
JP Hwang et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia
HY Lane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia
LS Godleski et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Risk of Weight Gain Associated with Antipsychotic Treatment: Results From the Canadian National Outcomes Measurement Study in Schizophrenia
Roger S. McIntyre et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2003)
Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study
R Apiquian et al.
SCHIZOPHRENIA RESEARCH (2003)
Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia
J van Bruggen et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2003)
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania
M Tohen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
TM Sanger et al.
JOURNAL OF AFFECTIVE DISORDERS (2003)
Amisulpride vs. risperidone in chronic schizophrenia: Results of a 6-month double-blind study
D Sechter et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Quetiapine: An effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade
S Tauscher-Wisniewski et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Olanzapine for the treatment of chronic refractory schizophrenia:: A 12-month follow-up naturalistic study
V Rodríguez-Pérez et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients
Y Barak et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study
JP Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease
A Breier et al.
BIOLOGICAL PSYCHIATRY (2002)
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
JM Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder
HC Margolese et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Weight and blood pressure change during clozapine treatment
SP Baymiller et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Switching to olanzapine from previous antipsychotics: A regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific
CT Lee et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia
SR Hirsch et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine
D Gothelf et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Antipsychotic-induced weight gain and therapeutic response: A differential association
P Czobor et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment
Y Barak
JOURNAL OF CLINICAL PSYCHIATRY (2002)
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two months
S Martin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2002)
Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study
MC Zanarini et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Weight gain and antipsychotic medication: Differences between antipsychotic-free and treatment periods
MM Simpson et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Quetiapine alone and added to a mood stabilizer for serious mood disorders
M Sajatovic et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Excess mortality in bipolar and unipolar disorder in Sweden
U Ösby et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial
JP Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
JM Azorin et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study
MI Butterfield et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2001)
Effects of long-term treatment with antipsychotics on serum leptin levels
A Herrán et al.
BRITISH JOURNAL OF PSYCHIATRY (2001)
The apparent effects of ziprasidone on plasma lipids and glucose
SJ Kingsbury et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
RR Conley et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
An open-label study of the treatment efficacy of olanzapine for Tourette's disorder
CL Budman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study
TM Sanger et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
BR Basson et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
RS McIntyre et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2001)
Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
BJ Kinon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Risperidone versus pimozide in Tourette's disorder: A comparative double-blind parallel-group study
R Bruggeman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
GD Tollefson et al.
BIOLOGICAL PSYCHIATRY (2001)
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine
BJ Kinon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
DC Henderson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
C Guille et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Long-term use of quetiapine in elderly patients with psychotic disorders
PN Tariot et al.
CLINICAL THERAPEUTICS (2000)
Efficacy of olanzapine in acute bipolar mania - A double-blind, placebo-controlled study
M Tohen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Share Paper
